v3.22.4
Revenue Recognition
3 Months Ended
Dec. 31, 2022
Revenue from Contract with Customer [Abstract]  
Revenue Recognition
4.
Revenue Recognition
Revenue Disaggregation
The following tables present our net revenues disaggregated by major geographic region, major product platform and disease state (Diagnostics segment only):
Net Revenues by Reportable Segment & Geographic Region
 
 
  
Three Months Ended December 31,
 
 
  
2022
 
  
2021
 
  
Inc (Dec)
 
Diagnostics-
  
  
  
Americas
   $ 33,182      $ 26,613        25
EMEA
     5,694        6,093        (7 )% 
ROW
     490        498        (2 )% 
    
 
 
    
 
 
    
 
 
 
Total Diagnostics
     39,366        33,204        19
    
 
 
    
 
 
    
 
 
 
Life Science-
                          
Americas
     5,859        8,137        (28 )% 
EMEA
     6,944        28,648        (76 )% 
ROW
     4,733        18,352        (74 )% 
    
 
 
    
 
 
    
 
 
 
Total Life Science
     17,536        55,137        (68 )% 
    
 
 
    
 
 
    
 
 
 
Consolidated
   $ 56,902      $ 88,341        (36 )% 
    
 
 
    
 
 
    
 
 
 
 
Net Revenues by Product Platform/Type
 
 
  
Three Months Ended December 31,
 
 
  
2022
 
  
2021
 
  
Inc (Dec)
 
Diagnostics-
  
  
  
Molecular assays
   $ 4,490      $ 4,752        (6 )% 
Non-molecular
assays
     34,876        28,452        23
    
 
 
    
 
 
    
 
 
 
Total Diagnostics
     39,366        33,204        19
    
 
 
    
 
 
    
 
 
 
Life Science-
                          
Molecular reagents
     7,574        31,488        (76 )% 
Immunological reagents
     9,962        23,649        (58 )% 
    
 
 
    
 
 
    
 
 
 
Total Life Science
     17,536        55,137        (68 )% 
    
 
 
    
 
 
    
 
 
 
Consolidated
   $ 56,902      $ 88,341        (36 )% 
    
 
 
    
 
 
    
 
 
 
Net Revenues by Disease State (Diagnostics segment only)
 
    
Three Months Ended December 31,
 
    
2022
    
2021
    
Inc (Dec)
 
Diagnostics-
                          
Gastrointestinal assays
   $ 21,273      $ 21,619        (2 )% 
Respiratory illness assays
     6,714        6,380        5
Blood chemistry assays
     4,620        78        5823
Other
     6,759        5,127        32
    
 
 
    
 
 
    
 
 
 
Total Diagnostics
   $ 39,366      $ 33,204        19
    
 
 
    
 
 
    
 
 
 
Royalty Income
Royalty income received from a third party related to sales of
H. pylori
products, totaled $1,650 and $1,040 in the three months ended December 31, 2022 and 2021, respectively. Such revenue is included as part of
Non-molecular
assays and Other within the Net Revenues by Product Platform/Type and Net Revenues by Disease State tables, respectively, above.
Reagent Rental Arrangements
Revenue allocated to the lease elements of Reagent Rental arrangements totaled $1,135 and $995 in the three months ended December 31, 2022 and 2021, respectively. Such revenue is included as part of net revenues in our Condensed Consolidated Statements of Operations.